2026-04-29T12:23:07Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/55162025-04-25T09:15:53Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Halcox, Julian P. author Tubach, Florence author López-García, Esther author De Backer, Guy author Borghi, Claudio author Dallongeville, Jean author Guallar, Eliseo author Medina, Jesus author Perk, Joep author Sazova, Oguen author Sweet, Stephen author Roy, Carine author Banegas, José Ramón author Rodríguez-Artalejo, Fernando author 2015 Aims To analyse the treatment and control of dyslipidaemia in patients at high and very high cardiovascular risk being treated for the primary prevention of cardiovascular disease (CVD) in Europe. Methods and Results Data were assessed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), which included a randomly sampled population of primary CVD prevention patients from 12 European countries (n = 7641). Patients' 10-year risk of CVD-related mortality was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm, identifying 5019 patients at high cardiovascular risk (SCORE >= 5\% and/or receiving lipid-lowering therapy), and 2970 patients at very high cardiovascular risk (SCORE >= 10\% or with diabetes mellitus). Among high-risk individuals, 65.3\% were receiving lipid-lowering therapy, and 61.3\% of treated patients had uncontrolled low-density lipoprotein cholesterol (LDL-C) levels (>= 2.5 mmol/L). For very-high-risk patients (uncontrolled LDL-C levels defined as >= 1.8 mmol/L) these figures were 49.5\% and 82.9\%, respectively. Excess 10-year risk of CVD-related mortality (according to SCORE) attributable to lack of control of dyslipidaemia was estimated to be 0.72\% and 1.61\% among high-risk and very-high-risk patients, respectively. Among high-risk individuals with uncontrolled LDL-C levels, only 8.7\% were receiving a high-intensity statin (atorvastatin >= 40 mg/day or rosuvastatin >= 20 mg/day). Among very-high-risk patients, this figure was 8.4\%. Conclusions There is a considerable opportunity for improvement in rates of lipid-lowering therapy use and achievement of lipid-level targets in high-risk and very-high-risk patients being treated for primary CVD prevention in Europe. PLoS One. 2015 Feb 18;10(2):e0115270 10.1371/journal.pone.0115270 1932-6203 PLOS ONE PLoS One. 2015 Feb 18;10(2):e0115270. 25692692 http://hdl.handle.net/20.500.12105/5516 RANDOMIZED-TRIALS ADULT-POPULATION PREVALENCE MANAGEMENT METAANALYSIS PREVENTION PROJECT STATINS EURIKA SPAIN Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe